Sertraline Induced Hepatotoxicity: A Case Report and Review of Literature

M Brahmania, Z Schwartz, G Rosenfeld, E Yoshida

Citation

Abstract
Introduction: Depression is a very common disorder amongst the general population and frequently encountered by most physicians (1). Selective Serotonin Re-Uptake Inhibitors (SSRI’s) have become the most commonly prescribed antidepressants due to their superiority compared to other antidepressants in the treatment of acute major depression (2). Although exceedingly rare, hepatotoxicity resulting from Sertraline use has been previously reported (3-7). In these case reports, the liver injury pattern was predominately hepatocellular. Unlike previous cases, we report the case of a patient presenting with markedly elevated cholestatic enzymes and painless jaundice while taking Sertraline for treatment of depression. Case Presentation: A 61-year-old Caucasian female presented with a history of fatigue, malaise, anorexia, and painless jaundice. She had taken Sertraline 100 mg daily for one year for management of her depression. However, due to a suboptimal therapeutic response, her dose was increased to 200 mg daily three weeks prior to presentation. She was also taking hormone replacement therapy (Premarin 0.625mg daily and Prometrium 100mg daily) to control menopausal symptoms. Liver enzymes obtained at the time of admission showed an ALT of 207 U/L, AST 161 U/L, Total Bilirubin 164 umol/L, Direct Bilirubin 135 umol/L, ALP 915 U/L, and GGT 4412 U/L. Laboratory and radiological investigations were inconclusive and a liver biopsy was consistent with a drug-induced hepatitis. Our patient’s symptoms and liver biochemistry improved following cessation of Sertraline therapy.

Conclusion: Heightened awareness amongst prescribing physicians is warranted for patients taking Sertraline in the treatment of depression for the development of hepatotoxicity. These effects may be compounded by patients also on hormone replacement therapy.

INTRODUCTION
Depression is a very common disorder amongst the general population and frequently encountered by most physicians. The international consortium of psychiatric epidemiology (ICPE) estimates the lifetime prevalence at 16.9% in the United States (1) and we anticipate a similar prevalence in Canada. Over the past twenty years, Selective Serotonin Re-Uptake Inhibitors (SSRI’s) have become the most commonly prescribed antidepressants. Recent evidence suggests Sertraline (a SSRI) may be superior in efficacy, acceptability, and tolerability compared to other antidepressants in the treatment of acute major depression (2). Side effects of Sertraline range from nausea and vomiting, headache and tremors, to sexual dysfunction. Asymptomatic elevations of transaminases have been documented in 0.8% of patients receiving Sertraline (3). Although exceedingly rare, hepatotoxicity resulting from Sertraline use has been previously reported. A review of the literature revealed eleven prior reports of Sertraline induced hepatotoxicity presenting with a predominately hepatocellular injury pattern or mixed obstructive and hepatocellular picture. Reported symptoms ranged from asymptomatic elevation of transaminases to fulminant hepatitis (4-7). In these case reports, the liver injury pattern was predominately hepatocellular. Unlike previous cases, we report the case of a patient presenting with markedly elevated cholestatic enzymes and painless jaundice while taking Sertraline for treatment of depression. Our patient’s symptoms and liver biochemistry improved following cessation of Sertraline therapy.

CASE PRESENTATION
A 61-year-old Caucasian female presented with a history of fatigue, malaise, anorexia, and painless jaundice. She was previously healthy, aside from a diagnosis of depression and anxiety for which she had taken Sertraline 100 mg daily for one year. However, due to a suboptimal therapeutic response, her dose was increased to 200 mg daily three weeks prior to presentation. In addition, she was taking hormone replacement therapy (Premarin 0.625mg daily and
Prometrium 100mg daily) for management of her menopausal symptoms for three years. Prior screening bloodwork obtained from the family physician revealed liver enzymes within normal limits, however, liver enzymes obtained at the time of admission showed an ALT of 207 U/L, AST 161 U/L, Total Bilirubin 164 umol/L, Direct Bilirubin 135 umol/L, ALP 915 U/L, and GGT 4412 U/L. There was no prior history of alcohol or substance abuse, nor was there any family history of liver disease or risk factors for viral hepatitis. An autoimmune workup, which included anti-nuclear antibody, anti-mitochondrial antibody, anti-smooth muscle antibodies and anti-tissue transglutaminase antibodies were all negative. Ceruloplasmin and alpha-1 antitrypsin levels were normal. Screening serologies for Hepatitis A, B and C were all negative. Abdominal imaging consisted of CT, ultrasound and MRCP all of which failed to reveal any intrahepatic or extrahepatic dilatation and the liver appeared normal. A Liver biopsy was consistent with cholestatic hepatitis, with bile accumulation throughout the lobules. There were no eosinophils present, nor was there any evidence of steatohepatitis or fibrosis (Figure 1, 2). The biopsy was consistent with either a viral or drug-induced hepatitis. Sertraline, Estrogen and Progesterone were discontinued upon admission however, despite minimal improvement in cholestatic enzymes, the patient was clinically stable and therefore, discharged from hospital 5 days later with close outpatient follow up. The patient resumed her hormone replacement upon discharge. Two weeks later, her liver enzymes had not improved and she had increased symptoms with more abdominal pain, nausea and drenching night sweats. She again stopped her Estrogen and Progesterone and by one month after cessation of therapy, she was improving both symptomatically and biochemically with liver enzymes being GGT 2868 U/L, ALP 679 U/L, Total Bilirubin 51 umol/L, Direct Bilirubin 45 umol/L, ALT 112 U/L, and AST 101 U/L.

Table 1: Liver enzyme pattern

|                | Admission | Post Admission Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Discharge (Day 7) | Follow Up (Day 12) | Follow Up (Day 18) | Follow Up (Day 25) | Follow Up (Day 27) | Follow Up (Day 30) | Follow Up (Day 34) | Follow Up (Day 40) | Follow Up (Day 44) | Follow Up (Day 48) | Follow Up (Day 54) | Follow Up (Day 60) | Follow Up (Day 66) | Follow Up (Day 70) | Follow Up (Day 78) | Follow Up (Day 85) | Follow Up (Day 93) | Follow Up (Day 100) |
|----------------|-----------|----------------------|-------|-------|-------|-------|-------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| AST            | 210       | 210                  | 210   | 210   | 210   | 210   | 210   | 210               | 210               | 210               | 210               | 210               | 210               | 210               | 210               | 210               | 210               | 210               | 210               | 210               | 210               | 210               | 210               |
| ALT            | 61        | 89                   | 89    | 89    | 89    | 161   | 89    | 89                | 89                | 89                | 89                | 89                | 89                | 89                | 89                | 89                | 89                | 89                | 89                | 89                | 89                | 89                | 89                |
| ALP            | 915       | 915                  | 915   | 915   | 915   | 915   | 915   | 915               | 915               | 915               | 915               | 915               | 915               | 915               | 915               | 915               | 915               | 915               | 915               | 915               | 915               | 915               |
| T. Bilirubin   | 164       | 164                  | 164   | 164   | 164   | 164   | 164   | 164               | 164               | 164               | 164               | 164               | 164               | 164               | 164               | 164               | 164               | 164               | 164               | 164               | 164               | 164               |
| Direct Bilirubin| 135       | 135                  | 135   | 135   | 135   | 135   | 135   | 135               | 135               | 135               | 135               | 135               | 135               | 135               | 135               | 135               | 135               | 135               | 135               | 135               | 135               | 135               |
| GGT            | 4412      | 4412                 | 4412  | 4412  | 4412  | 4412  | 4412  | 4412              | 4412              | 4412              | 4412              | 4412              | 4412              | 4412              | 4412              | 4412              | 4412              | 4412              | 4412              | 4412              | 4412              |
| LDH            | 170       | 170                  | 170   | 170   | 170   | 170   | 170   | 170               | 170               | 170               | 170               | 170               | 170               | 170               | 170               | 170               | 170               | 170               | 170               | 170               | 170               | 170               | 170               |
| INR            | 0.96      | 0.96                 | 0.96  | 0.96  | 0.96  | 0.96  | 0.96  | 0.96              | 0.96              | 0.96              | 0.96              | 0.96              | 0.96              | 0.96              | 0.96              | 0.96              | 0.96              | 0.96              | 0.96              | 0.96              | 0.96              | 0.96              |

Figure 1: An H&E stain which is demonstrating bile stasis and accumulation as well as hepatocyte degeneration and inflammatory cell accumulation, in keeping with a cholestatic liver pattern.

Figure 2: An H&E stain which is demonstrating bile stasis and accumulation as well as hepatocyte degeneration and inflammatory cell accumulation, in keeping with a cholestatic liver pattern.
DISCUSSION

Our patient represents a case of severe cholestatic hepatic injury secondary to Sertraline use with a significant increase in GGT and ALP, which improved four weeks following discontinuation of therapy. While several prior case reports have documented a predominant rise in hepatocellular enzymes following initiation of Sertraline use, our patient demonstrated a primarily cholestatic pattern of liver injury. Hepatotoxicity is a rare side effect occurring in 0.8% of study patients on Sertraline. Increase in enzyme levels usually develop in the first one to nine weeks of treatment and usually respond to discontinuation of the medication (3). Eleven cases of Sertraline induced hepatotoxicity have been reported thus far ranging from asymptomatic elevation of liver transaminases to acute hepatic failure (4-7). The mechanism of Sertraline induced hepatotoxicity remains unclear. Because SSRI’s inhibit the P450 2D6 enzyme system (8), they have the potential to increase the plasma concentration of other drugs metabolized by this enzyme. Prometrium is primarily metabolized by CYP 2C19 and CYP 3A4, which is a minor substrate of the 2D6 enzyme system. We postulate that an inhibition of 2D6 by Sertraline may have lead to an increase in circulating levels of Prometrium which in turn, may have contributed to the cholestatic pattern of liver injury seen in this patient. Alternatively, Sertraline is highly bound to plasma protein, and protein-binding displacement potentially may increase free serum concentrations of other co - administered drugs such as the Estrogen or Progesterone taken by our patient resulting in steroid induced hepatotoxicity. In our case, the viral, autoimmune, and metabolic causes of liver toxicity were excluded. Radiographic imaging did not reveal any pathology and the lack of eosinophils in the liver following biopsy suggests this was not an immune related phenomenon. We believe that the rapid increase in the Sertraline dose caused the hepatic toxicity which may have been potentiated by the concomitant use of Estrogen and Progesterone for hormone replacement.

CONCLUSION

Physicians of all specialties frequently encounter patients taking SSRI’s for treatment of depression and need to be aware of the potential serious and severe adverse side effect of hepatotoxicity related to the use of Sertraline. Physicians should be especially cautious when patients are taking hormone replacement therapy in conjunction with Sertraline as was illustrated by this case.

REFERENCES

Author Information

Mayur Brahmania, MD
Department of Medicine, Division of Gastroenterology, Vancouver General Hospital, University of British Columbia

Zachary Schwartz, MD
Department of Medicine, Division of Gastroenterology, Vancouver General Hospital, University of British Columbia

Greg Rosenfeld, MD
Department of Medicine, Division of Gastroenterology, Vancouver General Hospital, University of British Columbia

Eric Yoshida, MD
Department of Medicine, Division of Gastroenterology, Vancouver General Hospital, University of British Columbia